Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP‑1/GIP receptor agonist or an FGF‑21 analogue. All mice receiving combination therapy ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.